News

Domino’s Pizza reports earnings, Nvidia faces stiff competition in China, and Spirit AeroSystems finalizes a deal to transfer ...
Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...
Discover April's top dividend bargains! Explore high-quality blue-chip stocks like Merck & Schlumberger with strong yields, ...
Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business. The German ...
Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...
Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...
The latest health-related developments include Merck's acquisition talks with SpringWorks, disbandment of a US Justice ...
Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...